Gisele Dion - 01 Sep 2022 Form 4 Insider Report for Inhibikase Therapeutics, Inc. (IKT)

Role
Director
Signature
/s/ Milton H. Werner, Attorney-In-Fact
Issuer symbol
IKT
Transactions as of
01 Sep 2022
Net transactions value
$0
Form type
4
Filing time
06 Sep 2022, 17:08:35 UTC
Previous filing
03 Jun 2022
Next filing
16 Jun 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IKT Stock Option (right to buy) Award $0 +60,000 $0.000000 60,000 01 Sep 2022 Common Stock 60,000 $0.9500 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option shares vest 50% on each of the first two anniversaries of September 1, 2022.